EU Flu Day Launched Today by MEP Dolors Montserrat With Vaccines Europe’s Support
The first annual EU Flu Day is being launched today, 14 October 2020. The campaign seeks to highlight the importance of seasonal flu vaccination, particularly during the ongoing COVID-19 pandemic, and to address challenges for sustainable increase of flu vaccine coverage rates in Europe as a critical public health measure for healthcare systems sustainability.
It is a call to action for European citizens – particularly healthcare workers and at-risk groups – to make them aware of the need to be vaccinated against flu, in order to protect themselves, those around them as well as alleviating the stress on national health care systems.
The campaign is being spearheaded by Dolors Montserrat, a leading Member of the European Parliament (EPP, Spain) and Co-Chair of the Health Working Group. Montserrat is also a former Minister of Health in Spain. The campaign is being organised with the support of Vaccines Europe.
There are several activities being planned for EU Flu Day, including:
- #EUFluDay online campaign: EU Flu Day is an opportunity for policymakers and citizens alike to set an example. Everyone is encouraged to share a message about the importance of getting the flu vaccine on social media, using the hashtag #EUFluDay. EU policy makers have already begun posting messages of support (e.g. here, here, here), and several more are expected over the course of the day.
- EU Flu Day launch webinar: MEP Montserrat is holding a webinar to mark the launch of EU Flu Day, bringing together participants from the European Commission, World Health Organisation, European Parliament, healthcare professionals and the vaccines industry. It is titled “Flu vaccination as a public health measure during COVID-19” and is taking place from 14:00-16:00 CET on 14 October 2020. Speakers will share their views on optimal approaches to increase flu vaccine uptake during COVID-19. This will include how to overcome barriers with the uptake of seasonal flu vaccines, and how to ensure early supply forecast planning, given the long lead times for vaccine production. One key proposal is to extended window for flu vaccination, in order to meet the increased demand caused by a pandemic.
“We are calling on Europeans citizens, particularly health workers and at-risk groups, to get their seasonal flu vaccination, in order to protect themselves and others, and to avoid overwhelming national healthcare systems” said MEP Montserrat. “We want to do all we can to drive action to safeguard public health from seasonal influenza, especially in a COVID-19 setting. That’s why I am calling on EU policymakers to lead by example on 14 October – and throughout the entire season. With an annual EU Flu Day, we have an opportunity to improve flu vaccine uptake rates across the EU for future seasons. Only by taking steps like this can we safeguard public health in the face of a truly unprecedented crisis.”
The importance of flu vaccination during COVID-19
Seasonal flu vaccines are an essential part of the annual public health toolkit. It is estimated that there are up to 50 million cases of seasonal flu in Europe each year, causing up to 70,000 deaths. Seasonal flu also puts a large strain on healthcare systems, for example through hospitalisations. With the dual threat of seasonal flu and COVID-19, uptake of flu vaccines will be even more vital for public health during the 2020/2021 season to prevent the overwhelming of healthcare systems.
The WHO recommends that countries should aim for 75% flu vaccine coverage rate among at-risk groups. Yet no EU country currently meets this target. In fact, the latest available data shows an average uptake level of only 41% of those aged 65 and over, with the lowest score being only 7.7%, while some Member States are above 60%.
The COVID-19 pandemic has increased public awareness of the need for each person to take steps that protect the wider community – particularly those in at-risk groups. Seasonal flu vaccines are one of the most effective ways people can protect themselves, others and healthcare systems, particularly in a COVID-19 pandemic setting. Depending on local recommendations, flu vaccination might be prioritised to at-risk groups at the start of vaccination season, however it is important to note that people - both in and outside scope of risk groups - should consider vaccination even until January and beyond as peak phase of flu can fall to February or March.
Magdalena R. De Azero, Executive Director of Vaccines Europe, said: “The vaccine industry is currently working around the clock to develop, manufacture and supply COVID-19 vaccines. While these efforts continue, manufacturers have also managed to marginally increase their flu vaccine production to cope with increased demand. These efforts should be supported with effective national flu vaccination campaigns to ensure optimal access and uptake.” She added that “flu is an annual public health threat with or without the concurrent pandemic. Therefore, EU Flu Day needs to be a springboard for action. We need to translate ideas into reality – like expanding access to flu vaccines in new healthcare settings like pharmacies, and implementing targeted vaccination campaigns to meet demands of seasonal flu vaccination administration in a COVID-19 setting. Policymakers at both EU and national level have an essential role to play in achieving this – both this year and beyond.”
Vaccines Europe is a specialised group of the European Federation of Pharmaceutical Industries and Associations (EFPIA) that represents major innovative research-based vaccine companies as well as small and medium-sized enterprises operating in Europe which account for a large share of human vaccines used worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005465/en/
Contact information
Media
Magdalena R. De Azero
Executive Director, Vaccines Europe
magdalena.deazero@vaccineseurope.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreviPay Powers Walmart Business Pay By Invoice Offering16.9.2025 14:00:00 EEST | Press release
TreviPay, a fully managed B2B payments platform, has collaborated with Walmart Business to launch the next phase of the retailer’s Pay By Invoice program. The program enables eligible business customers to access a line of credit with 30-day net terms, powered by TreviPay’s next-generation payments and A/R automation technology. The offering is available for purchases online, in the Walmart Business app or in-store. A study of 300 global business buyers, conducted by Murphy Research for TreviPay, found 85% of buyers want the option to pay on net terms and are likely to buy more when they can pay this way. TreviPay’s Pay by Invoice offering enables buyers to defer payment, receive detailed invoices for streamlined recordkeeping and procurement, and manage cash flow more effectively. “The biggest opportunity in retail now is in B2B. Companies that capture this valuable segment will win with flexible payment options that integrate directly into the buying experience and maintain efficienc
Areteia Therapeutics Announces Positive Topline Results from the First Phase III Study of Oral Dexpramipexole in Eosinophilic Asthma16.9.2025 14:00:00 EEST | Press release
Areteia Therapeutics, Inc. (“Areteia”) today announced positive results from the Phase III EXHALE-4 efficacy and safety study of dexpramipexole as an add-on oral therapy in participants with eosinophilic asthma. “More than half of people with asthma have the eosinophilic subtype, yet there remains a profound need for easily administered oral treatment options that can help address their symptoms, which are often severe,” said Ian Pavord, MA, DM, Professor of Respiratory Medicine at the University of Oxford, UK and a member of Areteia’s Scientific Advisory Board. “Initial results from the Phase III EXHALE-4 study are extremely promising, particularly the statistically significant improvement in lung function and the reduction in eosinophils observed with dexpramipexole versus placebo, which show the potential for dexpramipexole to become the first oral treatment approved for eosinophilic asthma.” “We are pleased to report positive topline results for the EXHALE-4 Phase III study, which
NIQ Joins the Decentriq Network to Enable Secure Data Collaboration for Marketers and Agencies Across Europe16.9.2025 13:00:00 EEST | Press release
NIQ, a leading consumer intelligence company, is entering a strategic relationship with Decentriq to enable data collaboration for media use cases across Europe. Through the relationship, NIQ’s high quality consumer insights, including digital purchase data, will be available in Decentriq’s privacy-preserving clean rooms for the first time, enabling advertisers and agencies to utilize the data for audience profiling and closed loop measurement. Expanding beyond shopper insights NIQ is expanding its services to the data and media ecosystem through privacy-persevering clean rooms, opening up new opportunities for marketing and advertising agencies to enrich their first-party data insights, inform audience strategies, and measure sales outcomes. As Pierre Cholet, Chief Customer Officer at Decentriq, explains, “NIQ has long been a trusted name in understanding consumer purchasing behavior. Now, by integrating their data into Decentriq’s clean room, advertisers and agencies can leverage thi
Businesses Scale Transformation to Meet Regulatory, Technology and Customer Challenges, Finds Arthur D. Little Global Research16.9.2025 12:45:00 EEST | Press release
Transformation is now a way of life for global companies, with two-thirds (65%) undergoing wide-reaching or expanding organization-wide transformation initiatives. This is driven by regulatory change (including tariffs), technological disruption, and shifting customer needs, all of which are rated at 4.1/5 in importance. Confidence levels are high, with 95% expecting initiatives to deliver success, according to the inaugural Arthur D. Little (ADL) Global Transformation Study. Time frames vary significantly between regions. 71% have a four-to-six-year window for transformation, with 32% focused on five years. However, average timelines range from 3.2 years in North America to 4.9 years in the Middle East and 5.5 years in Asia-Pacific. There are also significant differences between who leads transformation efforts globally. While a third (32%) of companies have a Chief Transformation Officer (CTrO), adoption varies considerably by region. 53% of European companies have a CTrO, compared w
Reply Achieves the AWS Advertising and Marketing Technology Competency Thanks to the Contribution of the Data Reply and Storm Reply Teams16.9.2025 11:40:00 EEST | Press release
Reply [EXM, STAR: REY] has achieved the AWS Advertising and Marketing Technology Competency, the official recognition from Amazon Web Services certifying advanced technical and project expertise in the design and delivery of advertising and marketing solutions on AWS. This milestone was made possible thanks to the joint contribution of Storm Reply and Data Reply, both part of the Reply Group, with solid expertise in implementing cloud-native and data-driven solutions on the AWS platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916374888/en/ With this certification, Reply’s companies specialized in AWS services further consolidate their role as trusted technology partners for organizations looking to evolve their marketing and communication strategies through the advanced use of AWS cloud and AI technologies. The AWS Advertising and Marketing Technology Competency validates the ability of AWS Partners to deliver hig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom